The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department

Tunisie Medicale

Volumn 88, Issue 10, 2010, Pages 696-699

  Thabet, Lamia ^a   Memmi, Monia ^a   Turki, Amel ^a   Messadi, Amen Allah ^a  

^a Aziza Othmana Hospital   (Tunisia)

Author keywords

Acinetobacter baumannii; Fluoroquinolones use; Klebsiella pneumoniae; MRSA; Multidrug resistance bacteria; Pseudomonas aeruginosa

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BURN; BURN UNIT; DRUG USE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

BURNS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; FLUOROQUINOLONES; HUMANS; INTENSIVE CARE UNITS; SEPSIS;

EID: 77958116223     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Nseir S, Dipompeo C, Soubrier S, Delou P, Leuci H, Fabienne M, Durocher A. First generation fluoroquinolone use and subsequent emergence of multiple drugs resistant in the intensive care unit. Critical Care Medicine2005; 33:283-9.
2. Seir N, Ade Fr, Marquette CH, Durocher A. Impact de l'utilisation des fluoroquinolones sur ĺmergence des bactéries multiré sistants. Path.Bio2005; 53:470-5.
3. Hsueh P, Chen, Luh K. Relationship between antimicrobial use and antimicrobial resistance in Gram negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005;26:463-72.
4. Macdougall C, Harpe S, Powell J, Jhonson C, Edmont M, Polk R. Pseudomonas aeruginosa,Staphylococcus aureus and fluoroquinolone use. Emerging Infectious Diseases 2005; 11:1-14.
5. Mohr J, Jones A, Zeichner L, Wanger A, Tilloston G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private university affiliated teaching hospital: an 8 year experience: 1995-2002. Int J Antimicrob Agents 2004 ; 11:346-51.
6. C J Soussy. Comité de l'antibiogramme de la SFM. Bull. Soc. Fr. Microbiol. 2001.
7. www.who.int/drugresistance/whonet software.
8. Mise en place d'un réseau de surveillance de la consommation des antibiotiques parallèlement à certaines résistances bactériennes dans les établissements de soins de l'inter région Paris Nord. Protocole ATB 2005, CCLIN Paris Nord. http:www.ccr.jussien.fr/cclin.
9. Carmeli Y, Troillet, G N .Eliopoulos,.Samore M. Emergence of antibiotic resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. AAC 1999; 43:1379-82.
10. Lozzano J, Monnet D, Yague A,Campillos P, Gonzalo N, Burgos A. Surveillance de la résistance bactérienne et modélisation de sa relation avec les consommations d'antibiotiques au moyen de l'analyse des séries chronologiques. Bull.Soc.Fr. Microbiol 2002 ; 17 :
11. Elisabeth .Paramythiotou, J. Lucet, J. Timsit, D. Vanjak, C .Butz, A.Andremont. Acquisition of multidrug resistant P.aeruginosa in patients in intensive care units: role of antibiotic with antipeudomonal activity. CID 2004 ; 38: 670-4.
12. Patterson D «collateral damage from cephalosporin or quinolone antibiotic therapy.CID 2004; 38:41-5.
13. Charbonneau P, Parienti PP, Thibon P, Lebouvier G , Leclerq R.Facteurs d'acquisition du SARM à l'Hôpital :rôle des fluoroquinolones. 2005;35 :35-7
14. Neuhauser MM, Weinstein R, Rydman R, Danziger L, Quinn K. Antibiotic resistance among Gram negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-8.
15. Polk R, Jhonson C,Edmonnd M, wenze Rl. Trends in fluoroquinolone(FQ) prescribing in 35 us hospitals and resistance for P.aeruginosa a scope MMIT report. In proceeding of the interscience conference on antimicrobial agents and chemotherapy, Chicago American Society for Microbiology 2001(Abstract UL-1).